Treatment of Oral Thrush (Oropharyngeal Candidiasis)

First-Line Treatment Options

The Infectious Diseases Society of America recommends fluconazole 100 mg daily for 7-14 days as the gold standard for treating oral thrush, demonstrating superior efficacy compared to topical agents and other azoles 1, 2, 3, 4, 5
Itraconazole oral solution 200 mg daily for 7-14 days is equally efficacious to fluconazole and represents an appropriate alternative 1, 2, 4, 5
Clotrimazole troches 10 mg five times daily for 7-14 days can be used for mild cases, though symptomatic relapses occur sooner than with fluconazole 1, 2, 3, 4, 5
Nystatin suspension 100,000 U/mL (4-6 mL four times daily) or pastilles (200,000 U, 1-2 pastilles 4-5 times daily) for 7-14 days is effective but less convenient 1, 2, 4, 5
Miconazole 50 mg mucoadhesive buccal tablets once daily applied to the mucosal surface over the canine fossa are as effective as clotrimazole troches 3, 6

The Centers for Disease Control and Prevention recommends reserving long-term suppressive therapy for patients with frequent or disabling recurrences, particularly those with CD4 counts <50 cells/μL 1, 3, 4, 5, 6
Fluconazole 100 mg three times weekly is the recommended suppressive regimen 6
Alternative: Fluconazole 100-200 mg daily for continuous suppression 1, 7, 8

Itraconazole oral solution >200 mg daily (preferably 200 mg twice daily) achieves 64-80% response rates in fluconazole-refractory cases 3, 4, 5, 6
Posaconazole suspension 400 mg twice daily is efficacious in approximately 75% of refractory cases 3, 6
Voriconazole 200 mg twice daily (oral or IV) is effective for fluconazole-refractory infections 3, 6

Thorough disinfection of dentures is essential in addition to antifungal therapy for definitive cure 4, 5, 10, 6
Oropharyngeal fungal cultures are of little benefit, as many individuals have asymptomatic colonization and treatment frequently does not achieve microbiological cure 1, 2, 4, 6
Clinical diagnosis is sufficient to initiate treatment in most cases 1, 2, 4
Prior repeated azole exposure, especially fluconazole, is a risk factor for azole resistance 1, 2, 6, 8
Severe immunosuppression with CD4 counts <50 cells/μL is a risk factor for azole resistance 1, 2, 6, 8

Short courses of topical therapy rarely cause adverse effects beyond cutaneous hypersensitivity 7
Oral azoles may cause gastrointestinal upset 7
For therapy >21 days, consider periodic monitoring of liver chemistry studies due to potential hepatotoxicity 7

Symptoms of oral thrush significantly reduce oral intake of food and liquids, making prompt treatment essential for maintaining adequate nutrition and hydration in immunocompromised hosts 1, 2, 4, 5
Most patients experience improvement in signs and symptoms within 48-72 hours of initiating appropriate therapy 7

Avoid fluconazole in pregnancy due to teratogenic effects in high doses; four cases of craniofacial and skeletal defects have been reported after prolonged first-trimester use 7
Use topical agents (clotrimazole or nystatin) for pregnant patients 7